Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)

Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)

Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer, most NSCLC patients are at advanced stage at the time of diagnosis. For patients without sensitive driven-oncogene mutations, chemotherapy is still the main treatment at present, the overall prognosis is poor. Im...

Full description

Bibliographic Details
Main Authors: Caicun ZHOU, Jie WANG, Hong BU, Baocheng WANG, Baohui HAN, You LU, Zhehai WANG, Bo ZHU, Ziping WANG, Qibin SONG, Shengxiang REN, Dongmei LIN, Yayi HE, Xiaohua HU, Hongyun ZHAO, Shukui QIN
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2020-02-01
Series:Chinese Journal of Lung Cancer
Subjects:
lung neoplasms
cancer immunotherapy
immune checkpoint inhibitor
pd-1/pd-l1
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2020.02.01

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2020.02.01

Similar Items